KT-579

· Kymera Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KT-579, covering 2026-02-27 to 2026-02-27. Get the full timeline:

Most recent: Clinical Trial Update: First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants [Phase 1]